SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - (2024) vom: 03. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Levy, Matthew E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral agents |
|---|
| Anmerkungen: |
Date Revised 03.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/cid/ciad796 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366610783 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366610783 | ||
| 003 | DE-627 | ||
| 005 | 20240108141902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad796 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1248.xml |
| 035 | |a (DE-627)NLM366610783 | ||
| 035 | |a (NLM)38170452 | ||
| 035 | |a (PII)ciad796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Levy, Matthew E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Sars-CoV-2 | |
| 650 | 4 | |a antiviral agents | |
| 650 | 4 | |a electronic health records | |
| 650 | 4 | |a molnupiravir | |
| 650 | 4 | |a nirmatrelvir | |
| 700 | 1 | |a Burrows, Evanette |e verfasserin |4 aut | |
| 700 | 1 | |a Chilunda, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Pawloski, Pamala A |e verfasserin |4 aut | |
| 700 | 1 | |a Heaton, Phillip R |e verfasserin |4 aut | |
| 700 | 1 | |a Grzymski, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Goldman, Jason D |e verfasserin |4 aut | |
| 700 | 1 | |a McEwen, Lisa M |e verfasserin |4 aut | |
| 700 | 1 | |a Wyman, Dana |e verfasserin |4 aut | |
| 700 | 1 | |a Dei Rossi, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Isaksson, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Washington, Nicole L |e verfasserin |4 aut | |
| 700 | 1 | |a Basler, Tracy |e verfasserin |4 aut | |
| 700 | 1 | |a Tsan, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Ramirez, Jimmy |e verfasserin |4 aut | |
| 700 | 1 | |a Sandoval, Efren |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, William |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, James |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Shishi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g (2024) vom: 03. Jan. |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:03 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad796 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 03 |c 01 | ||